NFKB1 and ovarian cancer: Triptolide increases cellular ROS production by inhibiting complex I of the mitochondrial respiratory chain, and ROS further mediate the inactivation of the NF-κB survival pathway and cell apoptosis, thus reversing cisplatin resistance in ovarian cancer [182].